Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

First NW patient to receive OHSU/VAMC-invented MS drug
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
22nd Meeting of European Neurological Society
Takeda Submits a New Drug Application for Glatiramer Acetate in Japan for the Relapse Prevention of Multiple Sclerosis
The effect of Nintendo(R) Wii(R) on balance in people with multiple sclerosis: a pilot randomized control study.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis?
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
Time limited immunomodulatory functions of transplanted neural precursor cells.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species.
Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Disease-modifying treatments for progressive multiple sclerosis.
Generic interferon-beta
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.

Pages